-
Chardan Reiterates Sell On Esperion, Cites 'Lack Of Visibility' And 'Possibility Of Declining Efficacy'
Tuesday, July 28, 2015 - 11:52am | 319Read More...In a report published Tuesday, Chardan Capital Markets analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ: ESPR) with a $40 price target following the release of a phase II results from Study 014 which tested ETC-1002 over six weeks in patients with...
-
5 Biotech Stocks On Deck With The FDA
Tuesday, June 30, 2015 - 1:39pm | 482Read More...Some traders like to gamble on big news events that could have a dramatic effect on a particular stock. For example, the release of a company’s earnings report could cause an underlying stock to jump to new highs or drop to significant lows. While this may not interest all investors, it does...
